Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 65   

Articles published

JNJ 125.23 +0.77 (0.62%)
price chart
Johnson & Johnson Agrees to Settle Five Rispersal Suits
Johnson & Johnson agreed to settle five lawsuits over claims that its antipsychotic drug Risperdal caused increased breast-tissue growth in boys.
Former FDA chief David Kessler says J&J broke the law in promoting Risperdal  Philadelphia Inquirer (blog)
Done with Creative Review, J&J Turns Sights to Global Media Review
Johnson & Johnson has concluded its global creative agency review and is preparing to launch a global media review in markets not already in review, including North America, company executives said today.
Johnson & Johnson facing massive class action
Medical giant Johnson & Johnson is facing its third class action in Australia in as many years, with a case filed in the Federal Court yesterday which relates to a product called transvaginal mesh.
J.&J.'s Costs Take a Toll on Its Profit
Johnson & Johnson, which makes baby shampoo, artificial joints and such drugs as Remicade for immune disorders, reported net income of $2.97 billion, or $1.05 a share.
Johnson & Johnson Tops Forecasts on Lower Profit
J&J reaps benefit of Synthes acquisition  Financial Times
Five reasons to like Johnson & Johnson
Johnson & Johnson has made headlines over the past couple of years - for all the wrong reasons. Plagued by quality control problems and costly product recalls affecting key brands such as Tylenol, Benadryl and Motrin, the health care giant's reputation ...
Tylenol and the Legacy of J&J's James Burke
This post is in partnership with Knowledge@Wharton, the online research and business analysis journal of the Wharton School of the University of Pennsylvania.
J&J's Global Creative Review Nears Finish
Johnson & Johnson is close to concluding its global review of creative responsibilities for its over-the-counter brands and sources expect the bulk of the business to be consolidated at three roster shops: DDB, BBDO and JWT.
J&J Set to Consolidate Creative With Omnicom, WPP
Strong earnings reports from Mattel, Goldman Sachs, Johnson & Johnson help ...
Unexpectedly strong earnings reports from heavyweights like Mattel and Johnson & Johnson streamed in on Tuesday, helping fuel a rally on Wall Street.
Johnson & Johnson vs. Goldman & Goldman: Street Whispers
NEW YORK ( TheStreet) -- In Goldman Sachs' ( GS) Tuesday downgrade of Johnson & Johnson ( JNJ) to 'Sell,' Wall Street watchers might want to chalk up a win for reform... and bankers' love of advisory fees. The Goldman research arm's bearish outlook on ...
The Good, The Bad And The Ugly: Johnson & Johnson
They have all been recalled by Johnson & Johnson (NYSE:JNJ) between 2009 and 2012 for everything from the relatively inconsequential (Motrin caplets dissolving too slowly) to the very serious (bacterial contamination in Infant's and Children's Tylenol).